BACKGROUND: Injury of a spinal nerve or dorsal root ganglion (DRG) during selective spinal nerve blocks is a potentially serious complication that has not been adequately investigated. Our hypothesis was that local anesthetic injection into these structures may result in an inflammatory response and hyperalgesia. METHODS: We evaluated inflammatory and behavioral responses after injection of 4 L lidocaine or saline into the L5 spinal nerve or DRG of rats after partial laminectomy. Behavioral testing was performed before and after surgery to examine hyperalgesia in response to nociceptive mechanical stimulation of the foot. DRGs were harvested and stained, and rings of immunoreactive glial cells around neurons were counted. RESULTS: Animals demonstrated hyperalgesia on the ipsilateral paw up to 4 days after lidocaine injection into the DRG but not after injection into the spinal nerve. The number of glial fibrillary acid protein immunopositive glial cell rings, which represent activation of satellite cells, significantly increased in DRGs after injection of lidocaine into either the DRG or the spinal nerve. The number of glial fibrillary acid protein-positive cells in the lidocaine-injected group was significantly larger than in the saline-injected group. Sporadic OX-42 immunopositive cells, which represent activated microglia, were also seen in lidocaine-injected DRGs. Testing for Pan-T expression, which labels activated T lymphocytes, showed no positive cells. CONCLUSIONS: Lidocaine injection into the DRG may produce hyperalgesia, possibly due to activation of resident satellite glial cells. In a clinical setting, local anesthetic injection into the DRG should be avoided during selective spinal nerve blocks.
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DRG neurons convey information from peripheral sensory receptors to the central nervous system but, after peripheral nerve and DRG trauma or inflammation, they can also become an important source of increased nociceptive signaling through increased neuronal excitability and generation of ectopic discharges. 15, 16 It has been reported that topical application of local anesthetic to the DRG induces mechanical hyperalgesia in the rat, 17 but possible morphological changes in the DRG have not been studied. Whereas the histopathological and behavioral changes after peripheral nerve injection injury have been well investigated, there is little known about the consequences of injection within the DRG or adjacent spinal nerve.
Our study was motivated by the increasing use of SSNBs for diagnosis and treatment, and because there are important structural and functional differences between the DRG and peripheral nerves. 18 For instance, the DRG lacks a functional barrier between its interior milieu and both the blood and surrounding tissue, 19 which could alter the inflammatory response to injected materials. We therefore evaluated the neuroinflammatory response in rat DRGs after lidocaine or saline injection into nerve and DRG. We hypothesized that an inflammatory response may follow local anesthetic injection into the DRG and produce hyperalgesia.
METHODS

Experimental Animals
All experimental protocols were approved by the Ethics Committee of the University of Split, School of Medicine. Sixty-two Sprague-Dawley rats weighing 150 -200 g were used. Rats were randomly assigned to a group that had no surgery (control, n ϭ 14), and groups in which lidocaine was injected into the DRG (DRG lidocaine, n ϭ 22) or spinal nerve (nerve lidocaine, n ϭ 7). In additional groups, saline was injected into the DRG (DRG saline, n ϭ 13) or spinal nerve (nerve saline, n ϭ 6). In lidocaine and saline groups of DRG injections, rats were killed after the 5th (early response group, n ϭ 10 for lidocaine and n ϭ 4 for saline injection) or 16th postoperative day (late response group, n ϭ 12 for lidocaine and n ϭ 9 for saline injection).
Surgery
Animals were anesthetized with isoflurane (Forane ® , Abbott laboratories, Queenborough, UK) (3% in oxygen for induction, 2% for maintenance). An incision was made along the midline of the back and the right paravertebral region was exposed. Right paraspinal muscles were separated from transverse process at the L5 spinal level until the right L5 intervertebral foramen could be identified. For DRG and nerve injection, the L5 nerve and DRG were exposed using a micro bone rongeurs. Where indicated, the L5 DRG or the L5 nerve 5 mm distal to the ganglion was injected with 4 L of clinically used and commercially available lidocaine (Lidokain 2%, Belupo d.d., Koprivnica, Croatia; pH ϭ 6.0 -7.0, osmolality ϭ 311 mOsmol/kg, preservative free-data obtained from manufacturer) or 0.9% saline which duplicates the physical properties of lidocaine solution (pH 6.7-7.3, osmolality approximately 300 mOsml/kg) using a 29-gauge needle (BD Micro-Fine TM Plus, Becton Dickinson Insulin Syringe, Dublin, Ireland) with a beveled tip. The DRG injection was performed with about a 60 degree angle relative to the spine. The injected dose was chosen based on the fact that 4 L volume in a 1 mg rat DRG corresponds to the clinically relevant injection of the 4 mL into a 1 g human DRG.
Behavioral Testing
Behavioral testing was performed preoperatively and 1, 4, 8, and 15 days after surgery, using a method we have validated for identification of rats with neuropathic pain. 20 The plantar skin of each hindpaw of unrestrained rats was stimulated with a 22-gauge spinal anesthesia needle (Quincke tip) with enough pressure to indent but not puncture the skin. We tabulated the frequency of hyperalgesia-type responses (sustained shaking, licking, grooming, and/or chewing of the paw) to this noxious mechanical stimulation, which are clearly distinct from the normal quick reflexive withdrawal. The degree of hyperalgesia was expressed as the difference between the probability of hyperalgesia response of the right and left paw for each animal. Additional behavioral testing was performed immediately after lidocaine injection to validate accuracy and completeness of injection.
Immunohistochemistry
One day after sensory testing rats were anesthetized with isoflurane and killed. For immunohistochemistry, both right and left L5 ganglia, along with the contiguous part of the spinal nerve (approximately 5 mm), were harvested on 5th day or the 16th day. For paraffin sections, the DRGs were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (PBS, pH 7.4), embedded in paraffin wax and 5 m thick serial sections were cut transversally.
We used primary antibodies for anti-glial fibrillary acid protein antibody (GFAP Rabbit Polyclonal Antibody, Chemicon International, Temecula, CA) diluted 1:250, OX-42 antibody (Mouse antirat CD11B Monoclonal Antibody, Chemicon International, Temecula, CA) in dilution 1:250, and antirat Pan-T cells CBL 1503 (Chemicon Europe, Hampshire, UK) diluted 1:100. For secondary detection, we used corresponding LSAB ϩ System-HRP kits (Dako Cytomation, Glostrup, Denmark).
During quantification, the investigator was blind to the source of the tissue. A conservative analysis design was used in which each animal provided a single data point. Specifically, for each section examined (6 -8 sections per DRG), 2-4 images were acquired by digital camera Olympus DP-71 (Olympus America, Mellville, NY) using the same magnification (40ϫ) and display settings. On each micrograph, we then superimposed 1 square (200 ϫ 200 m) in which at least 80% of the surface was occupied by ganglion cells. For evaluation of GFAP staining, we counted the total number of neurons per square, as well as the number of neurons surrounded with rings of GFAP-immunoreactive satellite cells. We counted only those cells with more than 50% of circumference containing GFAP-positive satellite cells. The number of neurons surrounded with those rings was expressed as a percentage of all neurons. Using this methodology, we obtained between 120 and 177 data points for each rat. These values were averaged and used for statistical analysis to evaluate the between-rat main effect.
Statistical Analysis
Behavioral test scores and immunopositive cell counts were analyzed using analysis of variance with post hoc Newman-Keuls test (Statistica, StatSoft, Tulsa). Data are presented as mean Ϯ sem. Statistical significance was set at P Ͻ 0.05.
RESULTS
DRG Lidocaine Injection Produces Pain-Related Behavior
Analysis of the hyperalgesia-type response rate revealed a significant increase on the first two postoperative testing sessions in rats that had injections into the DRG with lidocaine in comparison with both control and saline-injected rats (F(4,80) ϭ 3.09; P ϭ 0.02) ( Fig. 1) . No other group showed any difference from control values. Since there were no differences in behavior between rats that had injections into the L5 DRG and nerve, we merged these groups.
All animals injected with saline showed normal sensory and motor behavior. The rats injected with lidocaine showed no responses to nociceptive mechanical stimulation immediately after DRG or spinal nerve injection, demonstrating accurate and complete delivery of lidocaine to the DRG and spinal nerve. Impaired motor behavior attributable to lidocaine injection was observed immediately after recovery from anesthesia, however, this resolved within 2 h, after which no signs of impairment could be found.
DRG Lidocaine Injection Produces Inflammation
Perineuronal satellite glia in injected DRGs were immunoreactive for GFAP, which was exhibited as rings of stained satellite cells around neurons. These rings, which represent activation of satellite glial cells resident in the DRG, 21 were present in statistically larger numbers in lidocaine-injected DRGs on day 5 (43% Ϯ 2.6%) and day 16 (59.5% Ϯ 3.5%) after surgery, compared to control (0.08% Ϯ 0.04%; Newman-Keuls test, q ϭ 5.4, P Ͻ 0.05 at day 5; q ϭ 35.7, P Ͻ 0.001 at day 16) ( Fig. 2) . A comparison of the lidocaine-injected group with the saline-injected group (32% Ϯ 3.5%, Newman-Keuls test, q ϭ 15.7, P Ͻ 0.001) revealed significant differences only at 16 days (Fig. 2) .
The appearance of activated satellite cell rings was similar in all DRGs with GFAP immunoreactivity (Figs. 3B and C). The ratio of DRG neurons surrounded with GFAP-positive satellite cell rings was not significantly increased in rats injected with saline. No differences in staining were observed for small versus large neurons.
Staining for OX-42, which represents activated microglia, was not sufficiently consistent to permit meaningful quantification, as we observed Ͻ10 immunopositive cells in all sections from lidocaine-injected DRG tissue (Fig. 3D ). However, no OX-42 stained cells were observed in any control, contralateral or salineinjected DRG sections. After Pan-T staining, which labels activated T lymphocytes, no labeled cells were detected in sections of either the injected or the noninjected DRGs.
Lidocaine Injection into the Spinal Nerve Produces an Inflammation Reaction in DRG but no Behavioral Changes
Although rats receiving injections of lidocaine or saline into the spinal nerve showed no hyperalgesia compared to control rats, injecting lidocaine and saline into the L5 nerve significantly increased activation of satellite glial cells around neurons in the connected DRG (Newman-Keuls test, q ϭ 10, P Ͻ 0.001 or q ϭ 6.7, P Ͻ 0.001, respectively; Fig. 4) , however, at levels significantly below those seen after direct DRG injection with lidocaine (23.8% Ϯ 3.6% positive after L5 nerve injection; 59.5% Ϯ 3.5% positive after L5 DRG injection; P ϭ 0.0008 by t-test). No differences in staining were observed for small versus large neurons. Neither OX-42 nor Pan-T staining was seen after spinal nerve injections.
DISCUSSION
We found that injection of clinically used concentrations of lidocaine into a DRG induced pain-related behavior and a marked inflammatory response in the DRG. This inflammation was a result of activation of resident and not hematogenous immunological cells. Although we also identified an inflammatory response in saline-injected rats, this was not accompanied with marked hyperalgesia, perhaps because this inflammatory response was significantly less than after lidocaine injection. Together, our findings raise the possibility that hyperalgesia after injection of lidocaine into the DRG may be attributed to an inflammatory response.
Our analyses revealed significantly more frequent hyperalgesia-type responses to nociceptive mechanical stimulation during the first two postoperative sessions in rats after injection of lidocaine into the DRG than in either noninjected controls or salineinjected rats. After injection into the spinal nerve, there was no significant difference in hyperalgesic responses among different experimental groups. These results indicate that injection of a local anesthetic in the DRG may cause neuropathic pain early after the injection, but that the injection into the spinal nerve will not have this consequence. The nerve injection site is further away from the DRG and injection into nerve produces a diminished inflammatory response compared to direct DRG injection, which may then be inadequate to provoke neuropathic pain.
These behavioral changes could not have been due to mechanical effects of the needle and pressure of injected liquid, 7 since we observed no behavioral changes in the group that was injected with an identical volume of saline. We propose that pain behavior after local anesthetic injection is the result of the anesthetic, as has been previously described after topical bupivacaine application. 17 Since the time pattern of GFAP activation and the peak behavioral response differ, activation of resident immunological cells is unlikely to be the only pathogenic factor, and additional mechanisms, perhaps abnormal neuronal activity, may contribute to the generation of hyperalgesia. However, a phenotypic switch induced by activation of satellite cells once initiated may persist for some time after the behavioral changes cease.
A substantial increase of GFAP immunoreactivity in the DRG is due to activation of resident immunological cells, namely the satellite glial cells, which in addition to an increase in resident or hematogenous macrophages also occurs in the DRG after peripheral nerve injury. 22 DRGs lack a functional blood-nerve barrier and may be readily invaded with leukocytes. Assuming that the same might happen after direct DRG injury, we stained DRGs with markers for nonresident immunological cells. There were no cells marked with Pan-T antibodies. However, OX-42 staining revealed sporadic immunopositive cells only in DRGs directly injected with lidocaine, as has been previously seen after peripheral nerve injury. 23 Although the OX-42 staining duplicated the appearance of satellite cells, the OX-42 antibody is highly specific and it has been previously confirmed that there is no crossreactivity between OX-42 cells and GFAP positive cells. 23 The reason for the similar appearance is the fact that OX-42 immunopositive cells can penetrate the glial sheath and end up lying close to the DRG cell, thus being indistinguishable from satellite cells in size and shape. 22, 23 As opposed to others, 24, 25 we did not find any differences in staining for small versus large neurons. These findings indicate that lidocaine injection into the DRG activates resident immunological cells, but it does not cause significant immigration of nonresident inflammatory cells into the DRG. Our group has previously described neuroinflammation in DRGs and spinal nerves in animals that developed neuropathic pain after peripheral nerve injury, using the same markers of inflammation as in the present study. 26 These findings, together with previous observations, 23, [27] [28] [29] indicate that the increase in the GFAP and OX-42 immunopositive cell counts in DRGs, spinal nerves or the dorsal horn of spinal cord may be associated with the onset of hyperalgesia after neural injury. The lack of a blood-nerve barrier in the DRG 19 may predispose this organ to inflammation since tissue-resident and circulating immune cells may more freely interact.
In conclusion, a potential complication of SSNB is unintended needle entry into a spinal nerve or DRG. The present study shows that injection of lidocaine into a DRG may cause neuroinflammation and neuropathic pain. This argues for making efforts to minimize the risk of local anesthetic DRG injection in clinical settings. 
